KLRS Q2 2021 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$180M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$33,000

Operating Income

-$38M

Net Income

-$38M

EPS (Diluted)

$-13.87

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$328M

Total Liabilities

$25M

Stockholders' Equity

$302M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$33,000	-$19,000	-73.7%
Operating Income	-$38M	-$12M	-209.8%
Net Income	-$38M	-$12M	-223.1%